Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma (Q34300883)

1 August 2017

title

Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma (English)

1 reference

1 August 2017

0 references

1 reference

1 reference

4

William Janssen

1 reference

1 August 2017

10

Vernon K Sondak

1 reference

1 August 2017

Shari Pilon-Thomas

1

1 reference

1 August 2017

Lisa Kuhn

2

1 reference

1 August 2017

Sabine Ellwanger

3

1 reference

1 August 2017

Erica Royster

5

1 reference

1 August 2017

Suroosh Marzban

6

1 reference

1 August 2017

Ragini Kudchadkar

7

1 reference

1 August 2017

Jonathan Zager

8

1 reference

1 August 2017

Geoffrey Gibney

9

1 reference

1 August 2017

Jeffrey Weber

11

1 reference

1 August 2017

James J Mulé

12

1 reference

1 August 2017

Amod A Sarnaik

13

1 reference

1 August 2017

publication date

1 October 2012

1 reference

1 August 2017

published in

Journal of Immunotherapy

1 reference

1 August 2017

volume

35

1 reference

1 August 2017

issue

8

1 reference

1 August 2017

page(s)

615-620

1 reference

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467830

Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467830

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467830

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467830

Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467830

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467830

Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467830

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467830

High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467830

4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467830

MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467830

Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467830

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

28 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22996367

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22996367

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1097/CJI.0B013E31826E8F5F

1 reference

1 August 2017

1 reference

1 August 2017

1 reference